Loading...
XNAS
EOLS
Market cap444mUSD
Dec 05, Last price  
6.85USD
1D
0.59%
1Q
-10.57%
IPO
-41.25%
Name

Evolus Inc

Chart & Performance

D1W1MN
XNAS:EOLS chart
P/E
—
P/S
1.67
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.04%
Rev. gr., 5y
50.12%
Revenues
266m
+31.76%
000034,925,00056,540,00099,673,000148,616,000202,085,000266,274,000
Net income
-50m
L-18.26%
-31,112,000-20,065,000-4,480,000-46,867,000-90,034,000-163,013,000-46,810,000-74,412,000-61,685,000-50,420,000
CFO
-18m
L-47.07%
-36,384,000-13,267,000-13,035,000-25,667,000-93,383,000-57,871,000-33,388,000-8,774,000-34,008,000-17,999,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
URL
https://www.evolus.com
IPO date
Feb 08, 2018
Employees
215
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT